An increasing body of evidence supports a key role for Keap1/Nrf2 pathway in kidney diseases and renal cell carcinoma (RCC), but data concerning the molecular basis and the clinical effect of its deregulation remain incomplete. The gene discussed is NFE2L2; the disease is hereditary clear cell renal cell carcinoma.